GSC Biological and Pharmaceutical Sciences
eISSN: 2581-3250 CODEN (USA): GBPSC2
Cross Ref DOI: 10.30574/gscbps
Journal homepage: https://gsconlinepress.com/journals/gscbps/

(REVIEW ARTICLE)

Check for updates

Directed Th2 polarization via controlled atopic immune activation as a therapeutic strategy in multiple sclerosis

Michael John Dochniak *

Alleamit Corporation, Minnesota, United States of America.

GSC Biological and Pharmaceutical Sciences, 2026, 34(01), 120-124

Publication history: Received on 01 December 2025; revised on 14 January 2026; accepted on 16 January 2026

Article DOI: https://doi.org/10.30574/gscbps.2026.34.1.0019

Abstract

Multiple Sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) characterized by immune cells attacking myelin, resulting in inflammation, demyelination, and progressive neurodegeneration. This process involves specific roles for Th1/Th17 cells and microglia. MS disease-modifying therapies (DMTs) employ various mechanisms, which generally fall under immunomodulation, broad immunosuppression, and immune cell depletion. The more potent therapies often involve immune cell depletion, and nearly all carry an increased risk of EAE infection and, despite their effectiveness, do not guarantee complete disease control or a cure for MS. Epidemiological, immunological, and experimental evidence suggests an inverse relationship between atopic (Th2-mediated) immune states and Th1/Th17-driven autoimmunity in multiple sclerosis. This review proposes a mechanistic framework in which controlled induction of Th2-skewed atopic immune signaling—via deliberate, antigen-specific activation of the allergy cascade—may counteract MS pathogenesis by redirecting immune polarity, suppressing pathogenic effector pathways, and modulating CNS-resident innate immune responses. Furthermore, the review outlines a biological rationale, supporting evidence, theoretical mechanism of action, and translational considerations for this immune redirection strategy, with particular emphasis on mast cell–mediated signaling, cytokine antagonism, and microglial phenotype modulation. Alleamit's patented hyperallergenic platform provides a mechanistically grounded method for inducing sustained Th2 polarization, while artificial intelligence (AI) assisted immune monitoring can enhance safety, personalization, and therapeutic precision. Collectively, this framework supports immune reprogramming as a viable disease-modifying strategy in MS and establishes a foundation for translational development.

Keywords: Allergy cascade; Autoimmunity; Extensive experimental autoimmune encephalomyelitis; Immune redirection; Mast cells; Microglia; Multiple sclerosis; Th2 polarization

1. Introduction

Multiple Sclerosis (MS) is widely understood as a chronic, immune-mediated disease of the central nervous system (CNS) where the immune system attacks myelin, leading to inflammation, demyelination, and subsequent axonal injury, causing varied neurological symptoms and disability. While traditionally called an autoimmune disease, its complex pathogenesis involves immune cells damaging myelin and axons in the brain and spinal cord, resulting in scar-like lesions (plaques) and disrupting nerve signals. While traditionally framed as an "overactive immune system," accumulating evidence demonstrates that MS reflects pathological immune polarization, rather than generalized immune hyperactivity [1,2].

The dominant immunological signature of MS includes exaggerated Th1 and Th17 responses, elevated interferon-γ (IFN-γ) and interleukin-17 (IL-17), and chronic activation of CNS-resident microglia [3,4,5]. Despite therapeutic

* Corresponding author: Michael John Dochniak

advances, current DMTs largely function by immune suppression or depletion, leaving unresolved the underlying misdirection of immune signaling.

This review examines a distinct and underexplored therapeutic paradigm: immune redirection through controlled Th2 polarization, which leverages the well-established antagonism between Th2-mediated atopic responses and Th1/Th17 autoimmunity.

2. Immunopathogenesis of Multiple Sclerosis

2.1. Adaptive Immune Polarization

EAE and human immunophenotyping studies confirm that MS pathology is driven by:

- Autoreactive $CD4^+$ Th1 and Th17 cells [6].
- Pro-inflammatory cytokine networks (IFN-γ, IL-17, GM-CSF) [7].
- Failure of regulatory immune counterbalances [8,9].

Th1/Th17 dominance is reinforced in MS through metabolic and cytokine feedback loops that suppress competing immune phenotypes [10].

2.2. Innate Immunity and CNS Persistence

MS progression often continues when peripheral immune activity is suppressed. This phenomenon is attributed to:

- Persistent microglial activation [11].
- Mast cell [12] and macrophage [13] involvement at the blood–brain barrier (BBB).
- Sustained neuroinflammatory signaling independent of lymphocyte trafficking [14,15].

Effective therapeutic strategies must address both peripheral immune polarity and CNS-resident immune behavior.

3. Th2 Immunity and the Allergy Cascade

3.1. Canonical Th2 Signaling

The Th2 immune program is characterized by:

- Cytokines: IL-4, IL-5, IL-13 [16].
- IgE class switching in B cells [17].
- Mast cell and eosinophil activation [18].
- Suppression of Th1 and Th17 differentiation [19].

These pathways are evolutionarily conserved to counterbalance pro-inflammatory immunity, particularly in parasitic and environmental antigen exposure.

3.2. Antagonism Between Atopy and Autoimmunity

Multiple epidemiological studies demonstrate an inverse association between allergic disease and MS prevalence or severity:

- Reduced MS incidence among individuals with asthma, allergic rhinitis, or eczema.
- Lower serum IgE levels were observed in MS patients compared to controls [20,21,22].

This antagonism suggests that sustained Th2 tone may exert a protective effect against autoimmune demyelination.

4. Mast Cells as Immune Modulators in the CNS

Mast cells, traditionally associated with allergies, are increasingly recognized as strategic immune regulators:

- Present in the meninges and perivascular CNS regions.
- Capable of altering BBB permeability.

- Release mediators that influence microglial phenotype and cytokine gradients [23,24].

Controlled mast cell activation has been shown to modulate neuroinflammation in EAE models, underscoring their relevance to MS pathophysiology [25].

5. Forced Atopy as a Programmable Immune Modulation Strategy

Alleamit's patented hyperallergenic topical formulations provide a repeatable, titratable, and non-systemic method for inducing sustained Th2-dominant immune signaling, offering a novel route to immune programming without systemic immunosuppression [26].

6. Proposed Mechanism: Controlled Atopic Immune Redirection in MS

Deliberate, antigen-specific induction of a controlled atopic response may therapeutically counter MS via:

- Suppression of Th1/Th17 differentiation through IL-4–mediated transcriptional antagonism.
- Immune metabolic interference, redirecting lymphocyte resources toward IgE-mediated pathways.
- Mast cell–driven modulation of CNS innate immunity, promoting anti-inflammatory microglial states.
- Reduction of autoreactive effector persistence, without broad immunosuppression.

This mechanism represents immune competition, not immune inhibition.

7. Therapeutic Strategy

7.1. Step 1: Cytokine evaluation and treatment to promote Th2 expression

Administration of cytokine treatment includes intravenous (IV) infusion and subcutaneous (SC) injection. The specific administration method, frequency, and dosage depend heavily on the type of cytokine (or cytokine inhibitor) being used and the patient's individual health status.

7.2. Step 2: Sensitization phase

- Topical or transdermal hyperallergenic composition applied over a period to initiate Type-1 hypersensitivity.
- Monitor IgE titers specific to chosen allergens to safely maintain a Type l hypersensitivity.

7.3. Step 3: Evaluation Phase

High-precision techniques for monitoring MS's autoimmune nature involve advanced imaging like functional MRI (fMRI), DTI, and PET scans to see inflammation and nerve damage; cerebrospinal fluid (CSF) analysis (with advanced biomarkers like IP-10, MALT1, and neurofilaments); and cutting-edge blood tests (like Next-Generation Sequencing or proteomics for immune cell profiling) to track disease activity, immune cell function, and personalize treatment, moving beyond standard MRI and lumbar punctures [27].

7.4. Artificial Intelligence

AI-Assisted Safety and Precision Immune modulation requires precise control to avoid excessive allergic responses or immune imbalance. AI-assisted platforms can enable real-time monitoring of cytokine profiles, patient-specific risk stratification, and adaptive dosing strategies.

Explainable AI models have already demonstrated significant potential and emerging utility in multiple sclerosis (MS) monitoring, disease trajectory prediction, and the optimization of personalized care, primarily by enhancing transparency, improving prediction accuracy over traditional methods, and providing actionable clinical insights [28].

Integrating AI with immune modulation allows for closed-loop safety control, ensuring therapeutic intent while minimizing adverse outcomes.

8. Challenges and Considerations

Key challenges include:

- Avoiding excessive mast cell activation or BBB disruption.
- Precise antigen selection to prevent epitope spreading.
- Dose titration to maintain controlled atopy without systemic hypersensitivity.

9. Conclusion

MS represents a disease of immune misdirection rather than immune excess. The controlled induction of Th2-skewed atopic signaling offers a theoretically grounded strategy to counteract Th1/Th17-driven neuroinflammation. While experimental validation remains necessary, the immunological logic, epidemiological signals, and mechanistic plausibility justify further investigation into immune redirection as a novel therapeutic paradigm in MS.

Compliance with ethical standards

Acknowledgments

Michael John Dochniak (Co-Founder) of Alleamit Corporation, Minnesota, and the United States of America.

Disclosure of conflict of interest

No conflict of interest to be disclosed.

Author Profile

Michael John Dochniak has authored several books on Alzheimer's disease, Artificial Intelligence, Autism Spectrum Disorders, and Climate Change through Cambridge Scholars Publishing and Nova Science Publishers.

References

[1] Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell, 1996;85(3):299-302.

[2] Lass Lassmann H. Multiple Sclerosis Pathology and its Reflection by Imaging Technologies: Introduction. Brain Pathology. 2018; (5):721-722.

[3] Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annual Review of Immunology. 2009; 27:485-517.

[4] Goverman J. Autoimmune T cell responses in the central nervous system. Nature Reviews Immunologhy. 2009; (6):393-407.

[5] Lotfi N, Thome R, Rezaei N, Zhang GX, Rezaei A, Rostami A, Esmaeil N. Roles of GM-CSF in the Pathogenesis of Autoimmune Diseases: An Update. Frontiers in Immunology. 2019; 10:1265.

[6] Kaskow BJ, Baecher-Allan C. Effector T Cells in Multiple Sclerosis. Cold Spring Harbor perspectives in medicine journal. 2018;8(4): a029025.

[7] Luchtman DW, Ellwardt E, Larochelle C, Zipp F. IL-17 and related cytokines involved in the pathology and immunotherapy of multiple sclerosis: Current and future developments. Cytokine Growth Factor Review. 2014;25(4):403-13.

[8] Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annual Review of Immunology. 2009; 27:485-517.

[9] Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain. 2006;129(Pt 8):1953-71.

[10] Hu H, Li H, Li R, Liu P, Liu H. Re-establishing immune tolerance in multiple sclerosis: focusing on novel mechanisms of mesenchymal stem cell regulation of Th17/Treg balance. Journal of Translational Medicine. 2024;22(1):663.

[11] Nan Y, Ni S, Liu M, Hu K. The emerging role of microglia in the development and therapy of multiple sclerosis. International Immunopharmacology. 2024;143(Pt 2):113476.

[12] Conti P, Kempuraj D. Important role of mast cells in multiple sclerosis. Multiple Sclerosis and Related Disorders Journal. 2016:77-80.

[13] Yang J, Fu Z, Zou Q, Li Z, Xing Y. Emerging Insights into the Role of Macrophages in Multiple Sclerosis: Pathogenesis and Potential Therapeutic Strategies. Journal of Inflammation Research. 2025; 18:14131-14146.

[14] Ransohoff RM. A polarizing question: do M1 and M2 microglia exist? Nature Neuroscience. 2016;19(8):987-91.

[15] Labzin LI, Heneka MT, Latz E. Innate Immunity and Neurodegeneration. Annual Review of Medicine. 2018; 69:437-449.

[16] Wynn TA. Type 2 cytokines: mechanisms and therapeutic strategies. Nature Reviews Immunology. 2015;15(5):271-82.

[17] Goetzl EJ. Th2 cells in rapid immune responses and protective avoidance reactions. Journal of Federation of American Societies for Experimental Biology. 2024;38(4): e23485.

[18] Koyasu S, Moro K. Type 2 innate immune responses and the natural helper cell. Immunology. 2011;132(4):475-81.

[19] Abbas AK, Lichtman AH, Pillai S, Sarah Henrickson. Cellular and Molecular Immunology. 11th ed. Elsevier; 2025.

[20] Tremlett HL, Evans J, Wiles CM, Luscombe DK. Asthma and multiple sclerosis: an inverse association in a case-control general practice population. QJM: An International Journal of Medicine. 2002;95(11):753-6.

[21] Pedotti R, De Voss JJ, Steinman L, Galli SJ. Involvement of both 'allergic' and 'autoimmune' mechanisms in EAE, MS and other autoimmune diseases. Trends In Immunology. 2003;24(9):479-84.

[22] Correale J, Farez M. Association between parasite infection and immune responses in multiple sclerosis. Annals of Neurology. 2007;61(2):97-108.

[23] Brown MA, Hatfield JK. Mast Cells are Important Modifiers of Autoimmune Disease: With so Much Evidence, why is There Still Controversy? Frontiers in Immunology. 2012; 3:147.

[24] Guo S, Wang H, Yin Y. Microglia Polarization From M1 to M2 in Neurodegenerative Diseases. Frontier in Aging Neuroscience. 2022; 14:815347.

[25] Secor, V.H., Brown, M.A., & Brown, M.A. (2000). Mast cells are essential for early onset and severe disease in EAE. Journal of Experimental Medicine. 191(5), 813–822.

[26] Dochniak MJ. Topical hyper-allergenic composition and method of treating using the same. USPTO 11,911,463. 02/27/2024.

[27] Pithakumar A, Basha S, Pai AR, Mahato KK. From pathogenesis to precision medicine: Targeting immune imbalance in multiple sclerosis. Ageing Research Reviews. 2026; 113:102921.

[28] Amin M, Martínez-Heras E, Ontaneda D, Prados Carrasco F. Artificial Intelligence and Multiple Sclerosis. Current Neurology and Neuroscience Reports. 2024;24(8):233-243.